233 related articles for article (PubMed ID: 30726104)
1. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
Wang J; Dean DC; Hornicek FJ; Shi H; Duan Z
FASEB J; 2019 May; 33(5):5990-6000. PubMed ID: 30726104
[TBL] [Abstract][Full Text] [Related]
2. Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.
He S; Fang X; Xia X; Hou T; Zhang T
Oncol Rep; 2020 Nov; 44(5):1929-1938. PubMed ID: 32901849
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
Ma H; Seebacher NA; Hornicek FJ; Duan Z
EBioMedicine; 2019 Jan; 39():182-193. PubMed ID: 30579871
[TBL] [Abstract][Full Text] [Related]
4. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Xu J; Xu S; Fang Y; Chen T; Xie X; Lu W
IUBMB Life; 2019 Mar; 71(3):347-356. PubMed ID: 30536701
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer.
Parvathareddy SK; Siraj AK; Masoodi T; Annaiyappanaidu P; Al-Badawi IA; Al-Dayel F; Al-Kuraya KS
J Ovarian Res; 2021 May; 14(1):69. PubMed ID: 34011401
[TBL] [Abstract][Full Text] [Related]
7. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
Yang L; Zhou F; Zhuang Y; Liu Y; Xu L; Zhao H; Xiang Y; Dai X; Liu Z; Huang X; Wang L; Zhao C
Br J Cancer; 2021 Feb; 124(3):645-657. PubMed ID: 33122847
[TBL] [Abstract][Full Text] [Related]
8. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.
Li X; Seebacher NA; Xiao T; Hornicek FJ; Duan Z
J Orthop Res; 2019 Feb; 37(2):510-521. PubMed ID: 30488489
[TBL] [Abstract][Full Text] [Related]
9. CDK9 is a prognostic marker and therapeutic target in pancreatic cancer.
Kretz AL; Schaum M; Richter J; Kitzig EF; Engler CC; Leithäuser F; Henne-Bruns D; Knippschild U; Lemke J
Tumour Biol; 2017 Feb; 39(2):1010428317694304. PubMed ID: 28231737
[TBL] [Abstract][Full Text] [Related]
10. Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.
Shen S; Dean DC; Yu Z; Hornicek F; Kan Q; Duan Z
J Cancer; 2020; 11(1):132-141. PubMed ID: 31892980
[No Abstract] [Full Text] [Related]
11. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
[TBL] [Abstract][Full Text] [Related]
12. LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis.
Rui X; Wang L; Pan H; Gu T; Shao S; Leng J
J Cell Mol Med; 2019 Feb; 23(2):865-876. PubMed ID: 30394665
[TBL] [Abstract][Full Text] [Related]
13. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
14. The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis.
Huang S; Qing C; Huang Z; Zhu Y
Diagn Pathol; 2016 Jun; 11(1):49. PubMed ID: 27283598
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
Shan B; Zhuo Y; Chin D; Morris CA; Morris GF; Lasky JA
J Biol Chem; 2005 Jan; 280(2):1103-11. PubMed ID: 15528190
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
17. CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
Kim J; Cho YJ; Ryu JY; Hwang I; Han HD; Ahn HJ; Kim WY; Cho H; Chung JY; Hewitt SM; Kim JH; Kim BG; Bae DS; Choi CH; Lee JW
Gynecol Oncol; 2020 Jan; 156(1):211-221. PubMed ID: 31776040
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma.
Shao YY; Hsu HW; Wo RR; Wang HY; Cheng AL; Hsu CH
Oncology; 2022; 100(11):602-611. PubMed ID: 36103810
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 9 (Cdk9) of fission yeast is activated by the CDK-activating kinase Csk1, overlaps functionally with the TFIIH-associated kinase Mcs6, and associates with the mRNA cap methyltransferase Pcm1 in vivo.
Pei Y; Du H; Singer J; Stamour C; Granitto S; Shuman S; Fisher RP
Mol Cell Biol; 2006 Feb; 26(3):777-88. PubMed ID: 16428435
[TBL] [Abstract][Full Text] [Related]
20. Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.
Lam F; Abbas AY; Shao H; Teo T; Adams J; Li P; Bradshaw TD; Fischer PM; Walsby E; Pepper C; Chen Y; Ding J; Wang S
Oncotarget; 2014 Sep; 5(17):7691-704. PubMed ID: 25277198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]